SVB Wealth’s Editas Medicine EDIT Stock Holding History

SVB Wealth’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-95	Closed	-$110	–	838
2025 Q1	$110	Buy	+95	New	+$140	﹤0.01%	1499

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SVB Wealth's EDIT Position: Q2 2025 in Review

SVB Wealth sold out of Editas Medicine (EDIT) in Q2 2025, closing a stake of 95 shares — an estimated $110 sold.

SVB Wealth first reported a position in EDIT in Q1 2025 and held it in 1 quarter. The position peaked at $110 in Q1 2025. 193 funds tracked by Wall St. Rank hold EDIT as of Q2 2025.

SVB Wealth reported no remaining Editas Medicine position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 95 Editas Medicine shares in Q2 2025, an estimated $110.
SVB Wealth first reported a position in Editas Medicine in Q1 2025 and held it in 1 quarter.
SVB Wealth's Editas Medicine position peaked at $110 in Q1 2025.
193 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.